Altria Group: Focus on Oral Tobacco Products and Growth

Dec.01.2022
Altria Group: Focus on Oral Tobacco Products and Growth
Altria Group's focus on oral tobacco products leads to expected growth in adjusted earnings per share by 4.5-6%.

US tobacco company Altria Group, Inc. (MO) appears well-prepared to tackle rising costs and weak cigarette sales by focusing on oral tobacco products, thanks to its strong pricing power. The company is expecting adjusted earnings per share between $4.81 and $4.89 in 2022, a growth of 4.5-6% compared to $4.61 in 2021.


Let's delve deeper and take a closer look.


Factors supporting Altria


Due to the serious health risks associated with smoking, consumers are turning to products with reduced risk or no smoke. Altria has been adapting to the changing market by offering a variety of oral, electronic, and heated tobacco products. Altria, through its subsidiary Helix Innovations, owns on!, a popular tobacco-derived nicotine (TDN) pouch product. Management believes that on! is worth mentioning as part of Altria's smoke-free product portfolio as oral TDN products are becoming more popular in the US due to their low-risk claims. In the third quarter of 2022, the net revenue of the oral tobacco products segment increased by 7% compared to the same period last year to $665 million due to price increases. The domestic shipment volume of this segment increased by 1.3%, mainly due to changes in trade inventory, industry growth rate, and calendar differences, with reported shipping volume soaring by about 70%. Additionally, the retail market share of oral tobacco increased compared to the previous quarter, reaching 5.2 share points in the third quarter.


Altria Group surprises with price, consensus, and earnings per share.


Tobacco giant Altria has remained strong thanks to its powerful pricing ability, even during periods of weak cigarette shipments and increased taxes. While higher prices may lead to decreased cigarette consumption, it appears that due to the addictive nature of cigarettes, smokers are willing to accept price hikes. In Q3 of 2022, higher pricing supported revenue in Altria's smokeable and oral tobacco product segments. Additionally, higher pricing helped the adjusted operating company income for both segments. This trend may continue to have room for growth.


Barrier or obstacle.


Cost inflation and rising natural gas prices were unfavorable factors in the third quarter. Additionally, wage costs increased. The continued presence of these factors remains a concern. Management's outlook for 2022 takes into account planned investments related to costs aimed at improving the digital consumer engagement system, strengthening research, development, and regulatory readiness costs for smokeless products, and supporting marketing activities for the company's smokeless products. The outlook also includes expectations for inflation in settlement agreement costs, as well as direct and indirect material costs. In the third quarter of 2022, Altria's net income decreased by 3.5% year-on-year to $6.55 billion, due to lower revenue from the wine segment divestment in October 2021 and decreased revenue from the combustible products segment. Excluding excise taxes, revenue decreased by 2.2% to $5.412 billion.


In the field of smoking products, net income decreased by 1.6% year-on-year to $5.882 billion due to decreased shipments and increased promotional investments. Domestic cigarette shipments fell by 9.2% year-on-year, primarily driven by industry decline and losses in retail market share. However, changes in trade inventory partially offset this impact. After adjusting for changes in trade inventory and other factors, estimates indicate that domestic cigarette shipments for smoking products decreased by 8%.


Bottom line


Overall, cigarette sales have been impacted by increased consumer health awareness and regulatory barriers. However, according to a third quarter earnings call with management, research suggests that despite price increases in the tobacco category compared to other categories, tobacco consumers are more likely to continue purchasing their preferred brands. Pricing power and advantages with smokeless tobacco products may keep Altria on a growth trajectory. The stock price of this third-ranked (hold) Zacks company has risen 1.5% over the past three months, compared to the industry's 1% increase.


2FIRSTS will continue to cover this topic, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

U.S. Court Rules Zyn Marketing Dispute Can Proceed, Rejects Philip Morris International’s Bid to Dismiss
U.S. Court Rules Zyn Marketing Dispute Can Proceed, Rejects Philip Morris International’s Bid to Dismiss
A U.S. federal court in Florida denied Philip Morris International and its subsidiaries’ motion to dismiss, allowing consumers to proceed with claims under the Florida Deceptive and Unfair Trade Practices Act alleging that Zyn nicotine pouches’ “tobacco-free” marketing is misleading. The court held that the allegations do not amount to a fraud claim and may move forward to the merits stage.
Dec.15 by 2FIRSTS.ai
Philippine FDA Requires Licenses for Vape Products with Medical Claims
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.
Dec.22 by 2FIRSTS.ai
Khmelnytskyi, Ukraine: counterfeit nicotine mixes and e-cigarette e-liquids seized, valued at over US$276,000
Khmelnytskyi, Ukraine: counterfeit nicotine mixes and e-cigarette e-liquids seized, valued at over US$276,000
According to UNN, law enforcement in Ukraine’s Khmelnytskyi region disrupted a group accused of selling illegally produced nicotine-containing mixtures and e-cigarette e-liquids without licenses or permits. The Prosecutor General’s Office said the overall value of the seized items exceeds UAH 12 million (about US$276,000). Motions were filed to arrest the seized property, and decisions are pending on necessary forensic examinations. (FX used: 1 UAH = US$0.023, as provided by the user.)
Jan.14 by 2FIRSTS.ai
Malaysia’s Kuching court fines vape retailer USD 4921 over “BEST VALUE FOR MONEY” poster promotion
Malaysia’s Kuching court fines vape retailer USD 4921 over “BEST VALUE FOR MONEY” poster promotion
A vape retail company in Kuching, Malaysia, was fined RM20,000 (about USD 4,921.86) by the Magistrates’ Court on January 19, 2026, after pleading guilty to an offence under Section 9(1) of the Control of Smoking Products for Public Health Act 2024 (Act 852). The case concerned a poster displayed at the company’s premises on October 6, 2025, carrying the slogan “BEST VALUE FOR MONEY.”
Jan.21 by 2FIRSTS.ai
BAT Malaysia names Mohd Nizom Sairi as board chairman effective January 1, 2026
BAT Malaysia names Mohd Nizom Sairi as board chairman effective January 1, 2026
BAT Malaysia announced that its independent non-executive director Datuk Seri Dr Mohd Nizom Sairi has been re-designated as board chairman effective January 1, 2026.
Jan.04 by 2FIRSTS.ai
Swedish Match to Revamp ZYN Lineup, Discontinue Four Nicotine Pouch Products in 2026
Swedish Match to Revamp ZYN Lineup, Discontinue Four Nicotine Pouch Products in 2026
According to Swedish Match’s website, the company plans to discontinue four ZYN nicotine pouch products in 2026, spanning different flavors and strength variants, and is directing consumers to existing substitute options.
Dec.19 by 2FIRSTS.ai